Navigation Links
MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
Date:5/14/2009

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will present three posters on its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program and one poster on its MAP0005 formoterol-budesonide combination asthma therapy program at ATS 2009, the International Conference of the American Thoracic Society, in San Diego on May 18, 2009.

The four posters can be viewed on Monday, May 18 between 8:15 a.m. and 4:00 p.m. Pacific Time. The presentations are titled:

  • "Unit Dose Budesonide (UDB): A New Submicron Dispersion of Nebulizable Budesonide Studied in 360 Children 12 Months to 8 Years Old with Mild to Moderate Persistent Asthma--The CASTLE I Study"
  • "A Novel Budesonide Formulation for Nebulization Significantly Improves the Amount of Drug Emitted over One Minute in a Simulated Pediatric Tidal Breathing Model"
  • "A Novel Aqueous Dispersion of Budesonide Significantly Improves the Aerodynamic Particle Sizing Distribution of Budesonide from Various Jet Nebulizers Compared to a Marketed Budesonide Suspension"
  • "Comparative Pharmacodynamics and Pharmacokinetics of MAP0005 (Formoterol-Budesonide Combination Particles Delivered via the Tempo(R) Inhaler) in Mild to Moderate Asthmatics"

Copies of the posters will be available under the Publications tab of the MAP Pharmaceuticals website on Monday, May 18.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
3. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
4. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
5. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
6. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
7. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
8. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
10. Vion Pharmaceuticals Reports 2009 First Quarter Results
11. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- ,Middle-aged adults with ... as likely as others to develop severe memory problems ... The British researchers said their findings could help doctors ... benefit from help for problem drinking. "We already ... levels of current alcohol consumption -- that understanding is ...
(Date:7/30/2014)... July 30, 2014 Florida A&M ... Renee Gordon and biochemistry professor Ngozi Ugochukwu, Ph.D., ... research as Fulbright Scholars. The prestigious Fulbright Scholars ... program that awards grants to students, faculty or ... research abroad. Both Gordon and Ugochukwu will conduct ...
(Date:7/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:7/30/2014)... NC (PRWEB) July 30, 2014 Chinese researchers ... mass in blood plasma can be used as a prognostic ... Click here to read the full article on the study ... Scientists in the Department of Respiratory Medicine at Shandong University ... diagnosed mesothelioma patients between 1995 and 2013. They ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 ... chiropractor Dr Steven Shoshany aims to help runners ... proven techniques to help athletes continue training. He has ... chiropractic, ART (Active Release Techniques), Cold Laser Therapy, Graston ... and injury free. , Dr Shoshany often combines ...
Breaking Medicine News(10 mins):Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Study Finds Common Blood Protein May Predict Mesothelioma Survival, Reports Surviving Mesothelioma 2Health News:Chiropractor Helping Runners Keep Going with New Integrated Treatment Protocols 2Health News:Chiropractor Helping Runners Keep Going with New Integrated Treatment Protocols 3
... WASHINGTON, June 9 Speaker Nancy Pelosi today ... Chairman Charles B. Rangel, Energy and Commerce Committee Chairman ... Miller briefed the Democratic Caucus on their draft health ... of doctors and plans, and guarantee affordable, quality health ...
... it,s no better than standard treatment, one expert says, ... the indigestion and heartburn that bother many women as ... Indigestion is common during pregnancy, with up to 80 ... reflux, belching and bloating. Symptoms tend to worsen over ...
... - Europe Cosmetiques and Probiox announced today that both ... respect to oxidative stress profiling. Under this agreement, Europe ... and Mexico. , According to Manon Pilon, Founder President ... the leader in the Medical SPA industry, and is ...
... 9 Allied World Assurance,Company (U.S.) Inc., a member ... AWH ), today announced an added service to ... States. The,complimentary service, called "Strategic Response(SM)," provides policyholders,with 24/7 ... of a catastrophe. , Gordon ...
... Calif., June 9 Jazz Pharmaceuticals, Inc. (Nasdaq: ... company,s first Phase III clinical trial of sodium oxybate ... this week during the Associated Professional Sleep Societies (APSS) ... the European League Against Rheumatism (EULAR) Congress in Copenhagen, ...
... , Programs Designed to Address High Risks for New Dialysis ... , DENVER, June 9 DaVita Inc. (NYSE: ... for those diagnosed with chronic kidney disease (CKD), today commended ... in Kidney Care (PEAK) campaign. Kidney Care Partners - ...
Cached Medicine News:Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:"Alliance between Europe Cosmetiques and Probiox brings new oxydative stress profiling technologies to North America" 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 2Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 4Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3
(Date:7/29/2014)... July 29, 2014  EnteroMedics Inc. (NASDAQ: ... technology to treat obesity, metabolic diseases and other gastrointestinal ... call on Thursday, August 7, 2014 at 11:00 AM ... quarter ended June 30, 2014 and to provide a ... The second quarter conference call may be accessed by ...
(Date:7/29/2014)... Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today reported net income for the quarter ended ... share, and non-GAAP net income of $94.0 million, or $0.88 ... year earlier was $93.3 million, or $0.81 per diluted share, ... diluted share.  Net sales for the quarter ...
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. ... and drug candidates targeting specific pathogens that cause serious ... the unusual market activity in the Company,s stock, the ... accordance with its usual practice. The Company stated that ... activity. About Synthetic Biologics, Inc. ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... New soluble polymer material,designed to stop bone bleeding ... new animal study just published in the Annals of ... recently published,research showing that the use of the new ... from the Medical University of South Carolina at Charleston,and ...
... AG (,Intercell,) to acquire Iomai Corporation (,Iomai,) in ... per share of Iomai,s common stock ... of approximately USD 189 million (EUR ... exchange for approximately 41 percent of Iomai,s ...
Cached Medicine Technology:Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: